Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the appointment of Lorin Jeffry “Jeff” Randall to its board of directors and Chairman of the Audit Committee. Mr. Randall currently serves on the boards of directors of Athersys, Inc. where he serves as Chairman of the Audit and Compensation Committees, and Acorda Therapeutics, Inc. where he serves on the Audit, Compliance and Nominations and Governance Committees.
“We’re at a critical inflection point for the Company and having Jeff’s expertise on the board and serving as Chairman of the Audit Committee will be extremely valuable as we work to advance voclosporin to market,” commented Charles Rowland, Chief Executive Officer of Aurinia.
Mr. Randall has over 30 years of experience serving in financial and operating roles spanning biotechnology, pharmaceuticals and manufacturing. He has led a number of companies through multi-million dollar financings and mergers and acquisitions. In addition to his current board positions, Mr. Randall served on the board of directors of Nanosphere, Inc. from 2008 to 2016, most recently as Chairman of the Board. From 2004 to 2006, Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company. Mr. Randall holds a Bachelor’s of Science in Mathematics and Accounting from Pennsylvania State University and a Master’s in Business Administration from Northeastern University.
“This is an especially exciting time for Aurinia,” added Jeff Randall. “I look forward to working with the accomplished Aurinia team in developing innovative treatments to improve long-term outcomes for patients living with debilitating and potentially life threatening diseases, such as lupus nephritis.” (Original Source)
Shares of Aurinia Pharmaceuticals closed today at $2.73, down $0.08 or -2.85%. AUPH has a 1-year high of $5.69 and a 1-year low of $1.42. The stock’s 50-day moving average is $3.10 and its 200-day moving average is $2.96.
On the ratings front, AUPH stock has been the subject of a number of recent research reports. In a report issued on November 16, Leerink Swann analyst Joseph Schwartz reiterated a Buy rating on AUPH, with a price target of $7.00, which implies an upside of 142% from current levels. Separately, on November 7, H.C. Wainwright’s Ed Arce reiterated a Buy rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Schwartz and Ed Arce have a yearly average return of 4.6% and 2.9% respectively. Schwartz has a success rate of 46% and is ranked #762 out of 4273 analysts, while Arce has a success rate of 35% and is ranked #1416.
Sentiment on the street is mostly bullish on AUPH stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $7.00, which represents a potential upside of 142% from where the stock is currently trading.
Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules for the treatment of lupus nephritis.